Ainos, Inc. filings document operating results, material agreements, governance matters, and the securities structure of a Nasdaq-listed company with AIMD common stock and AIMDW warrants. Form 8-K reports cover annual and quarterly financial results, AI Nose commercialization updates, distribution rights for AINOS AI Nose products and services, and amendments to product-development and patent-use arrangements.
The company’s proxy materials disclose director elections, shareholder voting matters, compensation information, and governance procedures. Its filings also describe relationships involving Taiwan Carbon Nano Technology Corporation and Ainos KY, including control and voting-power matters relevant to the company’s corporate governance and development agreements.
Ainos, Inc. reported Q1 2026 results showing minimal revenue and continued losses while shoring up liquidity with new financing. Revenue was just $161, down sharply from $106,207 a year earlier as the company shifted AI Nose activity from healthcare-adjacent uses toward earlier-stage industrial deployments.
The net loss narrowed to $2,459,800 from $3,286,022, helped by a 30% reduction in operating expenses, especially lower share-based compensation and SG&A. Cash and cash equivalents rose to $2,841,422 from $417,353 at year-end, driven by a new related-party loan of about $2,812,940 and $601,600 of net proceeds from an at-the-market equity program.
Total liabilities increased to $16,389,637, including $11,000,000 of related-party convertible notes, while stockholders’ equity declined to $5,691,946. Management states that recurring losses, an accumulated deficit of $69,980,128, and dependence on future financings create “substantial doubt” about the company’s ability to continue as a going concern.
Ainos, Inc. reported first quarter 2026 results showing minimal revenue and a narrower loss as it advances its AI Nose commercialization strategy. Revenue for the quarter was $161, compared with $106,207 a year earlier, reflecting the shift toward infrastructure-focused AI Nose deployments still in early stages.
The company reported a net loss of $2.46 million, improving from a $3.29 million loss in the prior-year quarter, as operating expenses declined about 30% year-over-year to approximately $2.28 million. Cash and cash equivalents rose to $2.84 million from $0.42 million, supported by a previously announced NT$90 million (approximately $2.8 million) financing, while total liabilities increased to $16.39 million and stockholders’ equity decreased to $5.69 million.
Operationally, Ainos continued deploying AI Nose under a roughly three-year $2.1 million commercial arrangement in backend semiconductor manufacturing, initiated pilots in front-end semiconductor environments, expanded healthcare infrastructure pilots, and further developed its Smell ID datasets and Smell Language Model to support long-term Smell AI platform commercialization.
Ainos, Inc. director Chiang Yao-Chung reported an open-market purchase of the company’s common stock through an indirect holding. On May 5, 2026, a spouse-related account bought 129 shares at $1.70 per share, bringing this indirect position to 829 shares.
In addition to these indirectly held shares, the reporting person also directly owns 90,880 shares of Ainos common stock as previously disclosed, indicating that the newly reported transaction is small compared with the existing direct holdings.
Ainos, Inc. director Chiang Yao-Chung reported two open-market purchases of the company’s common stock through indirect ownership by his spouse. He bought 100 shares at $1.75 per share on April 29, 2026 and 200 shares at $1.68 per share on April 30, 2026, increasing indirect holdings to 700 shares. A footnote states he also directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. investor Ting Chuan Lee has amended his Schedule 13D filing to reflect new equity compensation and updated ownership. He now reports beneficial ownership of 935,707 shares of common stock, representing 10.98% of the class.
The shares are subject to a voting agreement between Lee and Ainos Inc., a Cayman Islands corporation. On April 15, 2026, the issuer granted him 570,000 fully vested restricted stock units under the Ainos, Inc. 2023 Stock Incentive Plan. He reports no other transactions in the past 60 days aside from this grant.
Ainos, Inc. investor Chun-Jung Tsai filed an amended Schedule 13D reporting beneficial ownership of 686,999 shares of common stock, representing 8.06% of the class. These shares include 330,000 fully vested restricted stock units granted under the Ainos, Inc. 2023 Stock Incentive Plan.
The shares are subject to a voting agreement between the reporting person and Ainos Inc., a Cayman Islands corporation. Tsai states no current plans for major corporate actions but may review and change this position over time. The filer reports no other transactions in the past 60 days aside from the equity grant.
Ainos Inc. (Cayman Islands) filed Amendment No. 15 to its Schedule 13D reporting beneficial ownership of 491,263 shares of Ainos, Inc. common stock, representing 5.76% of the class. These 491,263 shares are owned directly by Ainos KY.
Ainos KY also holds sole voting power over a total of 4,807,506 shares through direct ownership and Voting Agreements with several shareholders, including ASE Test, Inc. and various individuals. The filing notes recent restricted stock unit grants on April 15, 2026 to three individuals, over which Ainos KY has sole voting discretion under a 2026 Voting Agreement.
Ainos, Inc. director TSAI CHUN-JUNG received equity compensation through restricted stock units that immediately converted into common shares. On the transaction date, 330,000 RSUs were granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan and then converted into 330,000 shares of common stock at a stated price of $1.61 per share. Following these transactions, TSAI directly holds 686,999 shares of Ainos common stock. These are compensation-related awards rather than open-market purchases or sales.
Ainos, Inc. director and CEO Tsai Chun-hsien reported equity awards and a conversion on April 15, 2026. He received 300,000 RSUs that vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 300,000 shares of Common Stock. A related award entry shows these 300,000 Common shares at $1.61 per share, bringing his directly held Common Stock to 710,372 shares after the transactions. No open-market purchases or sales were reported; all activity reflects compensation-related grants and a derivative conversion.
Ainos, Inc. director Lee Ting-chuan reported equity compensation activity involving restricted stock units (RSUs) that converted into common shares. On April 15, 2026, he received 570,000 RSUs granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 570,000 shares of common stock at a reported value of $1.61 per share. After these award and conversion transactions, Lee directly holds 935,707 shares of Ainos common stock. These are compensation-related acquisitions rather than open-market purchases or sales.